Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-16

Clinical Trial Update: Deucravacitinib for the Treatment of Palmoplantar Pustulosis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating deucravacitinib for palmoplantar pustulosis was terminated, with results posted on 2025-12-16.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sotyktu (Deucravacitinib)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Palmoplantar Pustulosis | Phase 4 | Status: TERMINATED | Results posted: 2025-12-16